Osteolytic bone diseases: physiological analogues of bone resorption effectors as alternative therapeutic tools.
The recent identification of key molecular protagonists involved in osteoclast biology has led to the development of new therapeutic approaches of osteolytic diseases using biological molecules which could compete with bisphosphonate therapy.